Amicus Therapeutics Inc (AM6 F) stock market data APIs
€7.1588
0(0%)
as of October 21, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
7.1588
Open
7.1588
High
7.1588
Low
7.1588
52 wk Range
4.8-10.8
Market Cap
2 227 M
Shares Outstanding
308 M
Revenue
571 M
EPS
-0.19
Beta
0.555
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 571 M
- EBITDA: 32 949 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
What Does Wall Street Think About Amicus Therapeutics (FOLD)?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) ...
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
Investors might want to bet on Amicus Therapeutics (FOLD), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings est...
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments
Amicus Therapeutics stock has recently seen a modest downward revision in its consensus analyst price target, adjusting from $16.09 to $15.36 per share. This change reflects ongoing debates among anal...
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics
For Immediate Release Chicago, IL – October 7, 2025 – Stocks in this week’s article are Amicus Therapeutics, Inc. FOLD, Micron Technology Inc. MU and General Dynamics Corp. GD. Bet on These 3 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
